|Dr. Richard Chin M.D.||Co-Founder, Chief Exec. Officer, Pres, Interim Chief Financial Officer and Director||619k||N/A||50|
|Ms. Denise M. Bevers||Co-Founder, Chief Operating Officer and Sec.||487.5k||N/A||50|
|Dr. Stephen Sundlof D.V.M., PH.D.||Chief Scientific Officer and Exec. VP of Regulatory Affairs & Quality||375.1k||N/A||66|
|Dr. Jennifer Elliott||VP of Legal Affairs and Intellectual Property||N/A||N/A||N/A|
|Dr. Noe Reyes D.V.M||Medical Director||N/A||N/A||N/A|
Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The companys product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for the treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs associated with equine metabolic syndrome. It is also developing biologics programs, such as KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) treatment for newborn foals; KIND-502 for the treatment of allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a novel biologics with certain advantages over antibodies, including bispecific binding. The company was founded in 2012 and is headquartered in Burlingame, California.
Kindred Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.